<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796167</url>
  </required_header>
  <id_info>
    <org_study_id>22-02-723-205</org_study_id>
    <secondary_id>1396075255</secondary_id>
    <nct_id>NCT05796167</nct_id>
  </id_info>
  <brief_title>Pimavanserin for Sleep in Parkinson Disease</brief_title>
  <official_title>Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Downstate Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g.,&#xD;
      visual hallucinations, delusions) and sleep problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a feasibility study to determine whether pimavanserin improves sleep quality in&#xD;
      patients with PD and visual hallucinations/delusions.&#xD;
&#xD;
      Patients will complete a Screening Visit to assess eligibility to participate in the study.&#xD;
&#xD;
      For more information, please contact Sofya Glazman, a study coordinator, at&#xD;
      sofya.glazman@downstate.edu&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2023</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>self-control, pilot study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of pimavanserin on sleep fragmentation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of arousals and the arousal index (arousals per hour of sleep) measured on polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on REM (Rapid Eye Movements) sleep behavior disorder</measure>
    <time_frame>6 weeks</time_frame>
    <description>Presence fo REM sleep without atonia (RWA) on polysomnograophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on sleep latency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time to first epoch on polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on total sleep time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Total sleep time measured on polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on sleep efficiency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Sleep Efficiency Index in percent is the ratio of total sleep time (based on polysomnography recordings) to time in bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on time in each sleep stage</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time in each sleep stage as measured on polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on subjective measure of REM Sleep behavior disorder</measure>
    <time_frame>6 weeks</time_frame>
    <description>RBDSQ (REM (Rapid Eye Movements) Sleep Behavior Disorder Screening Questionnaire to assess the most prominent clinical features of RBD. It is a 10-item, patient self-rating instrument with short questions to be answered by either 'yes' or 'no'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on subjective measures of sleep</measure>
    <time_frame>6 weeks</time_frame>
    <description>PDSS-2 (Parkinson's Disease Sleep Scale Version 2) total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores &gt; 18 are considered as relevant sleep disturbances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of pimavanserin on subjective measures of fatigue</measure>
    <time_frame>6 weeks</time_frame>
    <description>PFS-16 (Parkinson's disease Fatigue Scale): 16-item scale with the following scoring for each item: strong disagree -1, disagree - 2, neither agree or disagree - 3, agree - 4, strongly agree - 5; with overall score of â‰¥8 indicates the presence of significant fatigue.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Pimavanserin (Nuplazid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks for patients with Parkinson disease psychosis (e.g., visual hallucinations, delusions) and sleep problems</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin</intervention_name>
    <description>Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks</description>
    <arm_group_label>Pimavanserin (Nuplazid)</arm_group_label>
    <other_name>Nuplazid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Has a diagnosis of idiopathic PD according to UK (United Kingdom) PD Society Brain&#xD;
             Bank diagnostic criteria&#xD;
&#xD;
          2. Has a history of hallucinations or delusions associated with PD&#xD;
&#xD;
          3. Has a history of sleep disturbance&#xD;
&#xD;
          4. Is between the ages of 40 and 85&#xD;
&#xD;
          5. Has been on a stable dose of all PD medications for at least 30 days prior to&#xD;
             enrolment&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Has evidence of an atypical or secondary parkinsonian disorder&#xD;
&#xD;
          2. Has a contraindication to taking pimavanserin&#xD;
&#xD;
          3. Has contraindication to PSG&#xD;
&#xD;
          4. There has been a change to patient's neuropsychiatric medications including&#xD;
             dopaminergic medications (Sinemet, dopamine agonists, MAO(monoamine oxidaze)-B&#xD;
             inhibitors), SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin and&#xD;
             Norepinephrine Reuptake Inhibitors), dopamine-blocking agents, anti-epileptics,&#xD;
             anticholinergics, or benzodiazepines for at least 30 days prior to enrollment&#xD;
&#xD;
          5. Has traveled through 3 or more time zones within 60 days prior to study screening&#xD;
&#xD;
          6. Patient is a night-shift worker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daphne Robakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Downstate Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofya Glazman</last_name>
    <phone>7182707371</phone>
    <email>sofya.glazman@downstate.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daphne Robakis, MD</last_name>
    <email>daphne.robakis@downstate.edu</email>
  </overall_contact_backup>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 31, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>visual hallucinations</keyword>
  <keyword>delusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 17, 2023</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT05796167/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

